{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016659","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.734315+00:00","generated_at":"2026-05-18T17:30:53.757659+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Cardiff Oncology stockholders approve all proposals at 2025 annual meeting","bullets":["Seven director nominees elected, including CEO Mark Erlander, with between 20.4M and 21.2M votes each.","Ratification of BDO USA as independent auditor for FY2025: 36.3M for, 1.2M against.","Amendment to 2021 Equity Incentive Plan approved (16.9M for, 5.0M against); shares available increased to 12.15M.","Advisory say-on-pay vote on named executive officer compensation approved (18.9M for, 2.6M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016659","json":"https://secwatch.observer/filing/0001641172-25-016659.json","markdown":"https://secwatch.observer/filing/0001641172-25-016659.md","text":"https://secwatch.observer/filing/0001641172-25-016659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000164117225016659/0001641172-25-016659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000164117225016659/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:30:53.757659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}